| 蔡王苏.尿激酶联合短时透析在动静脉内瘘血栓形成早期中的应用[J].浙江中西医结合杂志,2017,27(5): |
| 尿激酶联合短时透析在动静脉内瘘血栓形成早期中的应用 |
| The application of urokinase combined with short-term dialysis treatment of early arteriovenous fistula thrombosis |
| 投稿时间：2016-08-16 修订日期：2016-08-25 |
| DOI： |
| 中文关键词: 尿激酶 短时透析 动静脉内瘘 血栓形成 |
| 英文关键词:Urokinase Short dialysis Arteriovenous fistula Thrombosis |
| 基金项目: |
|
| 摘要点击次数: 821 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的 探讨尿激酶联合短时透析在动静脉内瘘血栓形成早期中的临床疗效、预后及不良反应,为临床提供依据。方法 选择2015年3月～2016年4月本院收治的动静脉内瘘血栓形成早期患者62例,随机分为研究组和对照组,每组各31例,对照组患者应用尿激酶进行治疗,研究组患者应用尿激酶联合短时透析进行治疗。观察两组患者临床疗效、记录尿激酶用量、动静脉内瘘再通时间,比较两组患者再通情况及不良反应。并3个月后进行跟踪随访,比较两组再通者血栓复发率。结果 研究组患者尿激酶用量和再通时间分别为(16.33±2.90)×104U和(1.20±0.64)h,均低于对照组(23.94±3.18)×104U和(3.51±0.87)h,差异有统计学意义(P＜0.05)。研究组患者再通率和显效率分别为93.54%(29/31)和77.42%(24/31),高于对照组77.42%(24/31)和58.06%(18/31),差异具有统计学意义(P＜0.05),研究组患者不良反应和三个月复发率分别为12.90%(4/31)和10.34%(3/29),低于对照组29.03%(9/31)和25.00%(6/24),差异具有统计学意义(P＜0.05)。结论 尿激酶联合短时透析在动静脉内瘘血栓形成早期中,能够显著提高患者临床疗效,缩短血栓再通时间,减少尿激酶用量、不良结果和复发率,对于动静脉内瘘血栓患者具有重要临床意义。 |
| 英文摘要: |
| Objective To explore the clinical efficacy, prognosis and adverse reactions of urokinase combined with short-term dialysis treatment of early arteriovenous fistula thrombosis,and provide the basis for clinical.Methods 62 patients arteriovenous fistula thrombosis in early stage were selected in our hospital from March in 2015 to April in 2016.They were randomly divided into study group and control group,31 cases in each goup.Patients of control group treated with urokinase, study group given urokinase combined with short-term dialysis treatment.Observed clinical efficacy were,recorded the amount of urokinase,arteriovenous fistula recanalization time, compared recanalization and adverse reactions. And followed up three months later, compared recanalization of thrombosis recurrence rate. Results The urokinase dosage and reperfusion time of study group was (16.33±2.90)×104U and (1.20±0.64)h,lower than control group (23.94±3.18)×104U and (3.51±0.87)h,the statistical was difference significance (P<0.05).The recanalization rate and the effective rate of study group were 93.54% (29/31) and 77.42%(24/31),lower than the control group 77.42% (24/31) and 58.06% (18/31), higher than control group,the difference was statistically significant (P <0.05). Adverse reactions and three-month relapse rate of study group were 12.90% (4/31) and 10.34% (3/29), lower than the control group 29.03% (9/31) and 25.00% (6/24), the difference was statistically significant (P<0.05).Conclusion Urokinase Combined short-term dialysis arteriovenous fistula thrombosis early,can significantly improve clinical outcomes,shorten thrombus recanalization time and reduce the amount of urokinase,bad results and the recurrence rate of fistula thrombosis.It has important clinical intravenous significance for patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
